Bauman JE, Mulligan MS, Martins RG, Kurland BF, Eaton KD, Wood DE. Salvage lung resection after definitive radiation(>59Gy) for non-small cell lung cancer: surgical and oncologic outcomes. Ann Thorac Surg. 2008;86:1632–8.

Article  PubMed  Google Scholar 

Kuzmik GA, Detterbeck FC, Decker RH, Boffa DJ, Wang Z, Oliva IB, et al. Pulmonary resections following prior definitive chemoradiation therapy are associated with acceptable survival. Eur J Cardiothorac Surg. 2013;44:e66-70.

Article  PubMed  Google Scholar 

Yang CF, Meyerhoff RR, Stephens SJ, Singhapricha T, Toomey CB, Anderson KL, et al. Long-term outcomes of lobectomy for non-small cell lung cancer after definitive radiation treatment. Ann Thorac Surg. 2015;99:1914–20.

Article  PubMed  PubMed Central  Google Scholar 

Yang CJ, Gu L, Shah SA, Yerokun BA, D’Amico TA, Hartwig MG, et al. Long-term outcomes of surgical resection for stage IV non-small-cell lung cancer: a national analysis. Lung Cancer. 2018;115:75–83.

Article  PubMed  Google Scholar 

Jia J, Guo B, Yang Z, Liu Y, Ga L, Xing G, et al. Outcomes of local thoracic surgery in patients with stage IV non-small-cell lung cancer: a SEER-based analysis. Eur J Cancer. 2021;144:326–40.

Article  PubMed  Google Scholar 

Shimizu K, Ohtaki Y, Suzuki K, Date H, Yamashita M, Iizasa T, et al. Salvage surgery for non-small cell lung cancer after definitive radiotherapy. Ann Thorac Surg. 2021;112:862–73.

Article  PubMed  Google Scholar 

Ohtaki Y, Shimizu K, Suzuki H, Suzuki K, Tsuboi M, Mitsudomi T, et al. Salvage surgery for non-small cell lung cancer after tyrosine kinase inhibitor treatment. Lung Cancer. 2021;153:108–16.

Article  CAS  PubMed  Google Scholar 

Garassino MC, Gadgeel S, Speranza G, Felip E, Esteban E, Dómine E, et al. Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 Study. J Clin Oncol. 2023;41:1992–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brahmer JR, Lee JS, Ciuleanu TE, Caro RB, Nishio M, Urban L, et al. Five-year survival outcomes with nivolumab plus ipilimumab versus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer in CheckMate 227. J Clin Oncol. 2023;41:1200–12.

Article  CAS  PubMed  Google Scholar 

Bott MJ, Cools-Lartigue J, Tan KS, Dycoco J, Bains MS, Downey RJ, et al. Safety and feasibility of lung resection after immunotherapy for metastatic or unresectable tumors. Ann Thorac Surg. 2018;106:178–83.

Article  PubMed  PubMed Central  Google Scholar 

Baek J, Owen DH, Merritt RE, Shilo K, Otterson GA, D’Souza DM, et al. Minimally invasive lobectomy for residual primary tumors of advanced non-small-cell lung cancer after treatment with immune checkpoint inhibitors: case series and clinical considerations. Clin Lung Cancer. 2020;21:e265–9.

Article  CAS  PubMed  Google Scholar 

Bertolaccini L, Galetta D, Sedda G, de Marinis F, Spaggiari L. Safety analysis of salvage surgery for advanced stages or metastatic lung cancers. Thorac Cardiovasc Surg. 2022;70:273–6.

Article  PubMed  Google Scholar 

Smith A, Wali A, Montes A, Hadaki M, Harrison-Phipps K, Karapanagiotoue EM, et al. Salvage pulmonary resection in stages IIIb–IV lung cancer after treatment with immune checkpoint inhibitors case series and literature review. J Surg Oncol. 2022;125:290–8.

Article  CAS  PubMed  Google Scholar 

Beattie R, Furrer K, Dolan DP, Curioni-Fontecedro A, Lee DN, Frauenfelder T, et al. Two centres experience of lung cancer resection in patients with advanced non-small cell lung cancer upon treatment with immune checkpoint inhibitors: Safety and clinical outcomes. Eur J Cardiothorac Surg. 2021;60:1297–305.

Article  PubMed  Google Scholar 

Nagata S, Hamaji M, Ozasa H, Yamada Y, Ohsumi A, Date H. Salvage surgery after immune checkpoint inhibitors for advanced non-small cell lung cancer: potential association between immune-related adverse events and longer survival. Clin Lung Cancer. 2022;23:e321–4.

Article  CAS  PubMed  Google Scholar 

Ueno T, Yamashita M, Yamashita N, Uomoto M, Kawamata O, Sano Y, et al. Safety of salvage lung resection after immunotherapy for unresectable non-small cell lung cancer. Gen Thorac Cardiovasc Surg. 2022;70:812–7.

Article  PubMed  Google Scholar 

Imanishi N, Yoneda K, Taira A, Ichiki Y, Sato N, Hisaoka M, et al. Major pathologic response to alectinib in ALK-rearranged adenocarcinoma of the lung. Surg Case Rep. 2018;4:19. https://doi.org/10.1186/s40792-018-0430-7.

Article  PubMed  PubMed Central  Google Scholar 

Chikaishi Y, Uramoto H, Oka S, Nagata S, Shimokawa H, So T, et al. Discrepancy between the clinical image and pathological findings of non-small cell lung cancer harboring an epidermal growth factor receptor gene mutation that was surgically resected after gefitinib treatment. Case Rep Oncol. 2014;7:126–31.

Article  PubMed  PubMed Central  Google Scholar 

Nawashiro A, Tanaka F, Taira A, Shinohara S, Takenaka M, Kuroda K, et al. Salvage surgery following immuno-chemo-radiotherapy for advanced non-small cell lung cancer. Surg Case Rep. 2022;8:17.

Article  PubMed  PubMed Central  Google Scholar 

Fujita Y, Take N, Shinohara S, Mori M, Kanayama M, Takenaka M, et al. Achievement of pathological complete response with Osimertinib for EGFR-mutated lung adenocarcinoma. General Thorac Cardiovasc Surg Cases. 2023;2:60.

Article  Google Scholar 

Lin MW, Yu SL, Hsu YC, Chen YM, Lee YH, Hsiao YJ, et al. Salvage surgery for advanced lung adenocarcinoma after epidermal growth factor recepter tyrosine kinase inhibitor treatment. Ann Thorac Surg. 2023;116:111–9.

Article  PubMed  Google Scholar 

Chen YY, Yen YT, Lai WW, Huang WL, Chang CC, Tseng YL. Outcomes of salvage lung resections in advanced EGFR-mutant lung adenocarcinomas under EGFR TKIs. Thorac Cancer. 2021;12:2655–65.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xiong L, Li R, Sun J, Lou Y, Zhang W, Bai H, et al. Erlotinib as neoadjuvant therapy in stage IIIA (N2) EGFR mutation-positive non-small cell lung cancer: a prospective, single-arm, phase II study. Oncologist. 2019;24:157-e64.

Article  CAS  PubMed  Google Scholar 

Zhang Y, Fu F, Hu H, Wang S, Li Y, Hu H, et al. Gefitinib as neoadjuvant therapy for resectable stage II–IIIA non–small cell lung cancer: a phase II study. J Thorac Cardiovasc Surg. 2021;161:434-442.e2.

Article  PubMed  Google Scholar 

Zhong WZ, Chen KN, Chen C, Gu CD, Wang J, Yang XN, et al. Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer (EMERGING-CTONG 1103): a randomized phase II study. J Clin Oncol. 2019;37:2235–45.

Article  CAS  PubMed  Google Scholar 

Zhao Y, Cheng B, Chen Z, Li J, Liang H, Chen Y, et al. Toxicity profile of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung cancer: a systematic review and network meta-analysis. Crit Rev Oncol Hematol. 2021;160: 103305.

Article  PubMed  Google Scholar 

Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022;386:1973–85.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Provencio M, Nadal E, Insa A, García-Campelo MR, Casal-Rubio J, Dómine M, et al. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): An open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020;21:1413–22.

Article  CAS  PubMed  Google Scholar 

Provencio M, Serna-Blasco R, Nadal E, Insa A, García-Campelo MR, Rubio JC, et al. Overall survival and biomarker analysis of neoadjuvant nivolumab plus chemotherapy in operable stage IIIA non-small-cell lung cancer (NADIM phase II trial). J Clin Oncol. 2022;40:2924–33.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cascone T, William WN Jr, Weissferdt A, Leung CH, Lin HY, Pataer A, et al. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med. 2021;27:504–14.

Article  CAS  PubMed  PubMed Central  Google Scholar